CClinicalTrials.gg
CompletedNCT01751620Updated Feb 28, 2017

Project ACCEPT: Engaging Newly Diagnosed HIV+ Youth in Care

An interventional study of Project ACCEPT and HEALTH in HIV Positive Youth That Are Newly Engaged in Care, sponsored by University of North Carolina, Chapel Hill. Completed at 4 sites in United States. Open to participants aged 16 Years to 24 Years. Per ClinicalTrials.gov, last updated 2017-02-28.

Sponsored by University of North Carolina, Chapel Hill · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
167
Allocation
Randomized
Ages
16 Years to 24 Years
Sex
All
01

Study summary

The proposed study is a two-group randomized repeated measures design that will examine the efficacy of Project ACCEPT (Adolescents Coping, Connecting, Empowering and Protecting Together) to improve engagement in care among youth newly diagnosed with HIV at five AMTU sites across the United States. Youth will be randomized into one of two study arms; Project ACCEPT, the intervention, or HEALTH, the health education attention-controlled comparison condition. Both arms consist of two individual sessions followed by six group sessions and a final individual session which is expected to take approximately nine weeks after which youth will have four follow-up visits at the following time points:

  • post intervention (immediately after the last session);
  • 3 months post the last session;
  • 6 months post the last session; and
  • 12 months post the last session. The trial will be repeated in up to three waves.
02

Conditions studied

  • HIV Positive Youth That Are Newly Engaged in Care

Browse trials for

03

In context

HIV Seropositivity

210 studies on the registry are indexed under HIV Seropositivity; 10 are open to participants now.

This study's enrollment of 167 is above the median of 89 across 140 interventional studies indexed under HIV Seropositivity.

Browse HIV Seropositivity studies →

Lead sponsor

University of North Carolina, Chapel Hill is the lead sponsor of 1,340 studies on the registry; 133 are open to participants now.

Of its 155 completed or terminated interventional studies of FDA-regulated products, 136 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • HIV-infected and aware of his/her status as documented by medical record review or verbal verification by provider (i.e., medical or mental health care provider, case manager, social worker, etc.);
  • Received HIV diagnosis within the past 12 months (+ 3 months) at the time of consent/assent as documented by medical record review or verbal verification with referring professional (i.e., medical or mental health care provider, case manager, social worker, etc.);
  • Between the ages of 16-24 (inclusive) at the time of informed consent/assent;
  • Receives services at one of the selected AMTUs or one of their community partners;
  • Willing to participate in both the individual and group sessions;
  • Ability to speak and understand spoken English;
  • Able to understand and willing to provide signed informed consent/assent in English or Spanish; and
  • Willingness to provide signed informed consent or assent with parental/legal guardian permission as applicable.

Exclusion criteria

Exclusion Criteria:

  • Participated in a previous wave, if enrolling into Wave 2 or 3;
  • Intoxicated or under the influence of alcohol or other substances at the time of consent/assent;
  • Visibly distraught and/or visibly emotionally unstable (i.e., exhibiting suicidal, homicidal, or violent behavior) in the opinion of the site personnel would interfere with the ability to give true informed consent; and
  • Any concurrent participation in other behavioral studies. Permission from the protocol team may be provided for uncertain cases.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
167 participants (actual)

Study arms

  • Experimental
    Project ACCEPT

    Participants randomized to the intervention (Project ACCEPT) arm.

    Behavioral: Project ACCEPT

  • Active comparator
    HEALTH

    Participants randomized to the comparison (HEALTH) arm.

    Behavioral: HEALTH

Interventions

  • BehavioralProject ACCEPT

    The intervention, Project ACCEPT, combines weekly individual and group sessions that address a range of issues that impact engagement in care for youth living with HIV, including stigma, disclosure, health relationships, substance use, and future life plans.

    Also known as: Adolescents Coping, Connecting, Empowering and Protecting Together

  • BehavioralHEALTH

    The comparison condition, HEALTH, matches Project ACCEPT in number of sessions and duration. The weekly sessions will cover information on alcohol, drugs, HIV and other sexually transmitted diseases (STDs) to meet the ethical responsibility to provide risk reduction information to youth assigned.

06

What researchers measure

Primary outcomes

  1. Examine the efficacy of Project ACCEPT compared with an attention-controlled health education comparison intervention

    Conduct a randomized controlled trial to examine the efficacy of Project ACCEPT compared with an attention-controlled health education comparison intervention (HEALTH). The goals of the intervention are to improve engagement in care, decrease psychosocial barriers to care, and decrease sexual risk for youth newly diagnosed with HIV.

    Time frame: 3 years

Secondary outcomes

  1. Explore the relationship between HIV biomarkers and participant's level of engagement in care

    Explore the relationship between HIV biomarkers (i.e., CD4 and viral load) and participant's level of engagement in care.

    Time frame: 3 years

07

Study locations

4 sites
  • University of Miami School of Medicine
    Miami, Florida 33101, United States
  • Stroger Hospital and the CORE Center
    Chicago, Illinois 60612, United States
  • Wayne State University
    Detroit, Michigan 48201, United States
  • St. Jude Childrens Research Hospital
    Memphis, Tennessee 38105, United States
08

References and documents

Related links

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01751620
Lead sponsor
University of North Carolina, Chapel Hill
Collaborators
National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH)
Responsible party
Sponsor
First posted
Dec 18, 2012
Start date
Jan 2013
Primary completion
Jun 2015
Completion
Jun 2015
Last update
Feb 28, 2017

Study contacts

Sybil Hosek, PhD
study chair · Adolescent Trials Network
Gary Harper, PhD
study chair · Adolescent Trials Network

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion